Scholarlink

<p>Epithelial ovarian cancer (EOC) is a lethal gynecological malignancy. Ongoing research aimed to identify novel biomarkers and develop combined algorithms to improve diagnosis and prognosis prediction for EOC. RNA-seq related to EOC were obtained from the Recount 3 databases data. We categorized early, late stages versus control, all stages (I-IV) versus control, and early versus late stages for machine learning, deep learning model and explainable AI (XAI). The hub genes were selected by considering SHapley Additive exPlanations (SHAP) analysis. The expression of hub genes was validated in fresh tissue (34 EOC, and 33 benign neoplastic ovarian) and peripheral blood mononuclear cell (PBMC) from 39 EOC, and 33 benign neoplastic ovarian patients using real time-PCR. For late stage and also all stages versus control, three hub genes were selected including <i>SGO1</i>, <i>VTA1</i>, <i>RBM5-AS1</i> were mainly involved in cell cycle, estrogen signaling and vesicle trafficking. <i>SGO1</i>, and <i>VTA1</i> were increased significantly in both tissue and PBMC of EOC patients (<i>p</i> &lt; 0.05). <i>RBM5-AS1</i> was significantly decreased in EOC tissue as well as PBMC compared to benign neoplastic ovarian patients (<i>p</i> &lt; 0.05). <i>VTA1</i> and <i>RBM5-AS1</i> show promise as both diagnostic and prognostic markers, while <i>SGO1</i> may serve primarily as a diagnostic biomarker for EOC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of novel biomarkers for epithelial ovarian cancer through machine learning and explainable artificial intelligence using in silico and in vitro analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Zahra Chekini,
  • Toktam Dehghani,
  • Reza Khayami,
  • Amir Hossein Jafarian,
  • Marjaneh Farazestanian,
  • Malihe Hassanzadeh,
  • Alireza Pasdar

摘要

Epithelial ovarian cancer (EOC) is a lethal gynecological malignancy. Ongoing research aimed to identify novel biomarkers and develop combined algorithms to improve diagnosis and prognosis prediction for EOC. RNA-seq related to EOC were obtained from the Recount 3 databases data. We categorized early, late stages versus control, all stages (I-IV) versus control, and early versus late stages for machine learning, deep learning model and explainable AI (XAI). The hub genes were selected by considering SHapley Additive exPlanations (SHAP) analysis. The expression of hub genes was validated in fresh tissue (34 EOC, and 33 benign neoplastic ovarian) and peripheral blood mononuclear cell (PBMC) from 39 EOC, and 33 benign neoplastic ovarian patients using real time-PCR. For late stage and also all stages versus control, three hub genes were selected including SGO1, VTA1, RBM5-AS1 were mainly involved in cell cycle, estrogen signaling and vesicle trafficking. SGO1, and VTA1 were increased significantly in both tissue and PBMC of EOC patients (p < 0.05). RBM5-AS1 was significantly decreased in EOC tissue as well as PBMC compared to benign neoplastic ovarian patients (p < 0.05). VTA1 and RBM5-AS1 show promise as both diagnostic and prognostic markers, while SGO1 may serve primarily as a diagnostic biomarker for EOC.